Levetiracetam Hikma Farmacêutica (Portugal) (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal membranes and reduces abnormal electrical activity, helping to prevent the initiation and spread of seizure discharges in the brain.

The dosage of levetiracetam is individualized and determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber will set the appropriate dose and infusion rate according to clinical guidelines and patient needs.

Levetiracetam is classified as pregnancy category unknown, meaning safety data are limited. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug can be excreted in breast milk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. Its rapid intravenous formulation provides quick seizure control, while its mechanism via SV2A differs from sodium‑channel blockers, making it a useful option for patients who are refractory to or intolerant of other agents.

Store the product below 25 °C in its original packaging, protecting it from moisture and light. Avoid freezing the solution. Before administration, inspect the vial for particulate matter or discoloration and use aseptic technique to prevent contamination.

Levetiracetam Hikma is administered intravenously. The solution is typically infused over a period specified by the prescriber, often 15 minutes for loading doses, followed by maintenance infusions as required. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, blood disorders such as agranulocytosis, and emergence of suicidal thoughts or behavior. Patients should be monitored closely for any signs of these reactions and seek immediate medical attention if they occur.

Levetiracetam is contraindicated in patients with a known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for individuals with severe renal impairment who cannot be appropriately dose‑adjusted, and for those with a history of serious psychiatric disorders without close monitoring.